Prestige Consumer Healthcare (PBH) 10-Q 1 Nov 18 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2018	Oct. 26, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Consumer Healthcare Inc.
Entity Central Index Key	1,295,947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		51,737,977
Entity Emerging Growth Company	false
Entity Small Business	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues
Total revenues	$ 239,357	$ 258,026	$ 493,337	$ 514,599
Cost of Sales
Cost of sales excluding depreciation	100,647	112,580	212,716	224,337
Cost of sales depreciation	1,238	1,348	2,526	2,688
Cost of sales	101,885	113,928	215,242	227,025
Gross profit	137,472	144,098	278,095	287,574
Operating Expenses
Advertising and promotion	37,042	39,188	74,153	76,132
General and administrative	24,034	21,999	47,975	42,409
Depreciation and amortization	6,756	7,186	13,840	14,353
Gain on divestiture	(1,284)	0	(1,284)	0
Total operating expenses	66,548	68,373	134,684	132,894
Operating income	70,924	75,725	143,411	154,680
Other (income) expense
Interest income	(33)	(85)	(133)	(154)
Interest expense	27,103	26,921	53,143	53,331
Other expense (income), net	335	(432)	422	(506)
Total other expense	27,405	26,404	53,432	52,671
Income before income taxes	43,519	49,321	89,979	102,009
Provision for income taxes	12,678	18,616	24,672	37,545
Net income	$ 30,841	$ 30,705	$ 65,307	$ 64,464
Earnings per share:
Basic (in USD per share)	$ 0.59	$ 0.58	$ 1.25	$ 1.21
Diluted (in USD per share)	$ 0.59	$ 0.57	$ 1.24	$ 1.20
Weighted average shares outstanding:
Basic (in shares)	51,841	53,098	52,238	53,068
Diluted (in shares)	52,153	53,539	52,545	53,524
Comprehensive income, net of tax:
Currency translation adjustments	$ (2,145)	$ 2,716	$ (5,119)	$ 3,835
Unrecognized net gain on pension plans	0	0	0	1
Total other comprehensive (loss) income	(2,145)	2,716	(5,119)	3,836
Comprehensive income	28,696	33,421	60,188	68,300
Net sales
Revenues
Total revenues	239,354	257,930	493,308	514,417
Other revenues
Revenues
Total revenues	$ 3	$ 96	$ 29	$ 182

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Mar. 31, 2018
Current assets
Cash and cash equivalents	$ 36,910	$ 32,548
Accounts receivable, net of allowance of $14,433 and $12,734, respectively	153,849	140,881
Inventories	113,569	118,547
Deferred income tax assets	0	26
Prepaid expenses and other current assets	10,172	11,475
Total current assets	314,500	303,477
Property, plant and equipment, net	52,321	52,552
Goodwill	612,444	620,098
Intangible assets, net	2,715,070	2,780,916
Other long-term assets	3,360	3,569
Total Assets	3,697,695	3,760,612
Current liabilities
Accounts payable	66,251	61,390
Accrued interest payable	9,665	9,708
Other accrued liabilities	70,057	52,101
Total current liabilities	145,973	123,199
Long-term debt, net	1,895,835	1,992,952
Deferred income tax liabilities	440,853	442,518
Other long-term liabilities	21,796	23,333
Total Liabilities	2,504,457	2,582,002
Commitments and Contingencies — Note 16
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 53,609 shares at September 30, 2018 and 53,396 shares at March 31, 2018	536	534
Additional paid-in capital	474,137	468,783
Treasury stock, at cost - 1,871 shares at September 30, 2018 and 353 shares at March 31, 2018	(59,928)	(7,669)
Accumulated other comprehensive loss, net of tax	(24,434)	(19,315)
Retained earnings	802,927	736,277
Total Stockholders' Equity	1,193,238	1,178,610
Total Liabilities and Stockholders' Equity	$ 3,697,695	$ 3,760,612

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2018	Mar. 31, 2018
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 14,433	$ 12,734
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	53,609,000	53,396,000
Treasury stock (in shares)	1,871,000	353,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating Activities
Net income	$ 65,307	$ 64,464
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	16,366	17,041
Gain on divestiture	(1,284)	0
Loss on disposal of property and equipment	37	1,461
Deferred income taxes	339	16,321
Amortization of debt origination costs	3,021	3,494
Excess tax benefits from share-based awards	0	470
Stock-based compensation costs	4,328	4,726
Other	247	0
Changes in operating assets and liabilities:
Accounts receivable	(7,718)	(9,345)
Inventories	(4,145)	(3,409)
Prepaid expenses and other current assets	1,302	17,123
Accounts payable	4,187	8,008
Accrued liabilities	14,339	(11,869)
Other	(1,219)	55
Net cash provided by operating activities	95,107	108,540
Investing Activities
Purchases of property, plant and equipment	(5,074)	(4,785)
Acquisition of Fleet escrow receipt	0	970
Proceeds from divestiture	65,912	0
Net cash provided by (used in) investing activities	60,838	(3,815)
Financing Activities
Term loan repayments	(100,000)	(105,000)
Borrowings under revolving credit agreement	30,000	0
Repayments under revolving credit agreement	(30,000)	0
Proceeds from exercise of stock options	1,028	1,466
Fair value of shares surrendered as payment of tax withholding	(2,281)	(1,075)
Repurchase of common stock	(49,978)	0
Net cash used in financing activities	(151,231)	(104,609)
Effects of exchange rate changes on cash and cash equivalents	(352)	1,006
Increase in cash and cash equivalents	4,362	1,122
Cash and cash equivalents - beginning of period	32,548	41,855
Cash and cash equivalents - end of period	36,910	42,977
Interest paid	49,147	49,404
Income taxes paid	$ 2,444	$ 9,037

Business and Basis of Presentat

Business and Basis of Presentation	6 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products (prior to the sale of our Household Cleaning segment, as discussed in Note 3) to mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada), and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 8. Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., “ 2019 ”) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three and six months ended September 30, 2018 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2019 . These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2018 . Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Reclassification In accordance with Accounting Standards Update ("ASU") 2017-07, we have reclassified net periodic benefit costs related to our pension plans from general and administrative expense to other (income) expense. The impact of this reclassification on our financial statements was less than $1.0 million . Recently Adopted Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606 , including new FASB Accounting Standards Codification ("ASC") 606, which supersedes the revenue recognition requirements in FASB ASC 605. Along with amendments issued in 2015 and 2016, the new guidance eliminates industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue. The core principle of the new guidance is that an entity should recognize revenue for the transfer of goods and services equal to an amount it expects to be entitled to receive for those goods and services. The new standard also requires additional disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The new guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively by recognizing the cumulative effect of initially applying the guidance to all contracts existing at the date of initial application (the modified retrospective method). The ASU, as amended, is effective for annual reporting periods beginning after December 15, 2017. We adopted this guidance effective April 1, 2018 using the modified retrospective transition method and applied it to contracts that were not completed at the adoption date. See Note 2 for our revenue recognition policy. The effects of this recently adopted accounting pronouncement to our consolidated balance sheet as of April 1, 2018 are as follows: (In thousands) Balance March 31, 2018 New Revenue Standard Adjustment Balance April 1, 2018 Accounts receivable, net $ 140,881 $ 5,438 $ 146,319 Inventories 118,547 (1,768 ) 116,779 Other accrued liabilities 52,101 1,925 54,026 Deferred income tax liabilities 442,518 401 442,919 Retained earnings 736,277 1,344 737,621 In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost , which changes the presentation of net periodic benefit cost related to employer sponsored defined benefit plans and other postretirement benefits. Under this ASU, service cost should be included in the same income statement line item as other compensation costs arising from services rendered during the period, while other components of net periodic benefit pension cost should be presented separately outside of operating income. Additionally, only service costs may be capitalized in assets. Entities should apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. The guidance limiting the capitalization of net periodic benefit cost in assets to the service cost component should be applied prospectively. The standard is effective for annual reporting periods beginning after December 15, 2017. The adoption of this standard in the first quarter of 2019 required us to reclassify certain pension costs out of operating income and did not have a material impact on our consolidated financial statements. In March 2018, the FASB issued ASU 2018-05, Income Taxes (Topic 740) . The amendments in this update reflect the income tax accounting implications of the Tax Cuts and Jobs Act ("Tax Act"). See Note 14 for a discussion of the Tax Act, which was signed into law on December 22, 2017, and the impact it has had, and may have, on our business and financial results. In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income . The amendments in this update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. See Note 14 for a discussion of the Tax Act, which was signed into law on December 22, 2017, and the impact it has had, and may have, on our business and financial results. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. We have early adopted ASU 2018-02, and the adoption did not have a material impact on our consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. We adopted this standard effective April 1, 2018, and the adoption did not have a material impact on our consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments . The amendments in this update provide clarification and guidance on eight cash flow classification issues. For public companies, the amendments in this update are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We adopted this standard effective April 1, 2018, and the adoption did not have a material impact on our consolidated financial statements. Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans. The amendments in this update modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans and are effective for public companies for fiscal years ending after December 15, 2020. We do not expect the adoption of this standard to have a material impact on our financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements in Topic 820 and are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We do not expect the adoption of this standard to have a material impact on our financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) . The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our consolidated financial statements and whether to early adopt this ASU. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments . The amendments in this update provide financial statement users with more useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. The amendments to this update are effective for us for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases. The amendments in this update include a new FASB ASC Topic 842, which supersedes Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For public companies, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. In July 2018, further guidance on this topic was issued with ASU 2018-10, Codification Improvements to Topic 842, Leases, which affects narrow aspects of the guidance in ASU 2016-02, and with ASU 2018-11, Leases (Topic 842): Targeted Improvements, which provides an additional transition method to adopt the new lease standard as well as a practical expedient. The required effective dates for the amendments issued in July 2018 are the same as those for Topic 842. We plan to adopt the standard on April 1, 2019. We are in the process of aggregating and evaluating our lease arrangements. Adoption of this standard will result in a material increase in lease-related assets and liabilities recognized on our Consolidated Balance Sheet, but we are unable to quantify the impact at this time.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Nature of Goods and Services We recognize revenue from product sales. We primarily ship finished goods to our customers and operate in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning (this segment was sold on July 2, 2018). The segments are based on differences in the nature of products and geographical area. The North America and International OTC Healthcare segments market a variety of personal care and over-the-counter products in the following product groups: Analgesics, Cough & Cold, Women's Health, Gastrointestinal, Eye & Ear Care, Dermatologicals, and Oral Care. Prior to its sale, the Household Cleaning segment focused on the sale of cleaning products. Our products are distinct and separately identifiable on customer contracts or invoices, with each product sale representing a separate performance obligation. We sell consumer products under a variety of brands through a broad distribution platform that includes mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels, all of which sell our products to consumers. See Note 18 for disaggregated revenue information. Satisfaction of Performance Obligations Revenue is recognized when control of a promised good is transferred to a customer, in an amount that reflects the consideration that we expect to be entitled to receive in exchange for that good. This occurs either when finished goods are transferred to a common carrier for delivery to the customer or when product is picked up by the customer or the customer’s carrier. This represents a change in the timing of revenue recognition for some sales. Refer to the table above in Note 1 for disclosure of the adoption date impacts. Once a product has transferred to the common carrier or been picked up by the customer, the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the product. It is at this point that we have a right to payment and the customer has legal title. Variable Consideration Provisions for certain rebates, customer promotional programs, product returns, and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. We record an estimate of future product returns concurrent with recording sales, which is made using the most likely amount method which incorporates (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising. We participate in the promotional programs of our customers to enhance the sale of our products. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. The costs of such activities are recorded as a reduction to revenue when the related sale takes place. Estimates of the costs of these promotional programs are derived using the most likely amount method, which incorporates (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. At the completion of the promotional program, the estimated amounts are adjusted to actual results. Practical Expedients Due to the nature (short duration) of our contracts with customers, we apply the practical expedient related to remaining performance obligations disclosure. Remaining performance obligations relate to contracts with a duration of less than one year , in which we have the right to invoice the customer at the time the performance obligation is satisfied for the amount of revenue recognized at that time. Accordingly, we have elected the practical expedient available under ASC 606 not to disclose remaining performance obligations for our contracts. The period between when control of the promised products transfers to the customer and when the customer pays for the products is one year or less. As such, we do not adjust product consideration for the effects of a significant financing component. The amortization period of any asset resulting from incremental costs of obtaining a contract would be one year or less. We expense incremental direct costs of obtaining a contract (broker commissions) when the related sale takes place. We account for shipping and handling costs as fulfillment activities and therefore recognize them upon shipment of goods. The impact of adopting ASC 606 on our Condensed Consolidated Statements of Income and Comprehensive Income is as follows: Three Months Ended September 30, 2018 Six Months Ended September 30, 2018 (In thousands) As Reported Impact of Change Without Adoption of ASC 606 As Reported Impact of Change Without Adoption of ASC 606 Total revenues $ 239,357 $ (16,165 ) $ 223,192 $ 493,337 $ (22,110 ) $ 471,227 Cost of sales $ 101,885 $ (6,204 ) $ 95,681 $ 215,242 $ (8,396 ) $ 206,846 Total operating expenses $ 66,548 $ (440 ) $ 66,108 $ 134,684 $ (579 ) $ 134,105 Income before income taxes $ 43,519 $ (9,521 ) $ 33,998 $ 89,979 $ (13,135 ) $ 76,844 Provision for income taxes $ 12,678 $ (2,771 ) $ 9,907 $ 24,672 $ (3,752 ) $ 20,920 Net income $ 30,841 $ (6,750 ) $ 24,091 $ 65,307 $ (9,383 ) $ 55,924

Divestiture

Divestiture	6 Months Ended
	Sep. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
Divestiture	Divestiture On July 2, 2018, we sold the Comet®, Spic and Span®, Chore Boy®, Chlorinol® and Cinch® brands, as well as associated inventory. These brands represented our Household Cleaning segment. As a result of this transaction, we received proceeds of approximately $65.9 million and recorded a pre-tax gain on sale of $1.3 million . The net proceeds were used to repay debt. The following table sets forth the components of the assets sold and the pre-tax gain recognized on the sale in July 2018: (In thousands) July 2, 2018 Components of assets sold: Inventory $ 6,644 Property, plant and equipment, net 653 Goodwill 6,245 Intangible assets, net 49,315 Assets sold 62,857 Total purchase price received 65,912 (3,055 ) Costs to sell 1,771 Pre-tax gain on divestiture $ (1,284 )

Inventories

Inventories	6 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) September 30, 2018 March 31, 2018 Components of Inventories Packaging and raw materials $ 13,704 $ 13,112 Work in process 237 157 Finished goods 99,628 105,278 Inventories $ 113,569 $ 118,547 Inventories are carried and depicted above at the lower of cost or net realizable value, which includes a reduction in inventory values of $3.3 million and $4.2 million at September 30, 2018 and March 31, 2018 , respectively, related to obsolete and slow-moving inventory.

Goodwill

Goodwill	6 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Household Consolidated Balance - March 31, 2018 Goodwill $ 711,104 $ 32,919 $ 71,405 $ 815,428 Accumulated impairment loss (130,170 ) — (65,160 ) (195,330 ) Balance - March 31, 2018 580,934 32,919 6,245 620,098 2019 Reductions — — (6,245 ) (6,245 ) Effects of foreign currency exchange rates — (1,409 ) — (1,409 ) Balance - September 30, 2018 Goodwill 711,104 31,510 65,160 807,774 Accumulated impairment loss (130,170 ) — (65,160 ) (195,330 ) Balance - September 30, 2018 $ 580,934 $ 31,510 $ — $ 612,444 As discussed in Note 3, on July 2, 2018, we sold our Household Cleaning segment. As a result, we decreased goodwill by $6.2 million . Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. At February 28, 2018 , during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2018 . We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test. We also considered our market capitalization at February 28, 2018 , which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increasing competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future. As of September 30, 2018 , no events have occurred that would indicate potential impairment of goodwill.

Intangible Assets, net

Intangible Assets, net	6 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Lived Trademarks Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2018 $ 2,490,303 $ 441,314 $ 2,931,617 Reductions (30,562 ) (34,889 ) (65,451 ) Effects of foreign currency exchange rates (5,117 ) (287 ) (5,404 ) Balance — September 30, 2018 2,454,624 406,138 2,860,762 Accumulated Amortization Balance — March 31, 2018 — 150,701 150,701 Additions — 11,181 11,181 Reductions — (16,136 ) (16,136 ) Effects of foreign currency exchange rates — (54 ) (54 ) Balance — September 30, 2018 — 145,692 145,692 Intangible assets, net — September 30, 2018 $ 2,454,624 $ 260,446 $ 2,715,070 As discussed in Note 3, on July 2, 2018, we sold our Household Cleaning segment. As a result, we decreased our indefinite-lived intangibles by $30.5 million and our net finite-lived trademarks by $18.8 million . Amortization expense was $5.4 million and $11.2 million for the three and six months ended September 30, 2018 , respectively, and $5.8 million and $11.7 million for the three and six months ended September 30, 2017 , respectively. Based on our amortizable intangible assets as of September 30, 2018 , amortization expense is expected to be approximately $10.7 million for the remainder of fiscal 2019 , $21.5 million in fiscal 2020 , $21.0 million in fiscal 2021 and $20.6 million in each of fiscal 2022 , 2023 and 2024 . Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. The date of our annual impairment review was February 28, 2018, and we recorded impairment charges in our March 31, 2018 financial statements. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value. We utilize the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record impairment charges in the future. As of September 30, 2018 , no events have occurred that would indicate further potential impairment of intangible assets.

Other Accrued Liabilities

Other Accrued Liabilities	6 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) September 30, 2018 March 31, 2018 Accrued marketing costs $ 28,457 $ 21,473 Accrued compensation costs 6,523 10,591 Accrued broker commissions 2,113 1,487 Income taxes payable 12,735 1,901 Accrued professional fees 3,877 2,244 Accrued production costs 6,388 7,392 Other accrued liabilities 9,964 7,013 $ 70,057 $ 52,101

Long-Term Debt

Long-Term Debt	6 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt At September 30, 2018 , we had $75.0 million outstanding on the asset-based revolving credit facility entered into January 31, 2012, as amended (the "2012 ABL Revolver") and an additional borrowing capacity of $85.0 million . Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) September 30, 2018 March 31, 2018 2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. $ 600,000 $ 600,000 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00%, with a floor of 1.00%, due on January 26, 2024. 838,000 938,000 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022. 75,000 75,000 Long-term debt 1,913,000 2,013,000 Less: unamortized debt costs (17,165 ) (20,048 ) Long-term debt, net $ 1,895,835 $ 1,992,952 As of September 30, 2018 , aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans, 2012 ABL Revolver and the indentures governing the 6.375% senior unsecured notes due 2024 (the "2016 Senior Notes") and the 5.375% senior unsecured notes due 2021 (the "2013 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2019 (remaining six months ending March 31, 2019) $ — 2020 — 2021 — 2022 475,000 2023 — Thereafter 1,438,000 $ 1,913,000

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. FASB ASC 820, Fair Value Measurements , requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2013 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. See summary below detailing the carrying amounts and estimated fair values of these borrowings at September 30, 2018 and March 31, 2018 . September 30, 2018 March 31, 2018 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2016 Senior Notes $ 600,000 $ 606,000 $ 600,000 $ 610,500 2013 Senior Notes 400,000 400,000 400,000 402,000 2012 Term B-5 Loans 838,000 838,000 938,000 939,173 2012 ABL Revolver 75,000 75,000 75,000 75,000 At September 30, 2018 and March 31, 2018 , we did not have any assets or liabilities measured in Level 1 or 3.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on our common stock through September 30, 2018 . During the three months ended September 30, 2018 , we made no repurchases of common stock. During the three months ended September 30, 2017 , we repurchased 933 shares of common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the three months ended September 30, 2017 were at an average price of $51.60 . During the six months ended September 30, 2018 and 2017 , we repurchased 68,939 shares and 20,549 shares, respectively, of common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the six months ended September 30, 2018 and 2017 were at an average price of $33.09 and $52.33 , respectively. All of the repurchased shares have been recorded as treasury stock. During the six months ended September 30, 2018 , we repurchased 1,449,750 shares of our common stock in conjunction with our share repurchase program. The repurchases were at an average price of $34.47 per share, totaled $50.0 million , and have been recorded as treasury stock.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Accumulated other comprehensive loss consisted of the following at September 30, 2018 and March 31, 2018 : (In thousands) September 30, 2018 March 31, 2018 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (25,517 ) $ (20,398 ) Unrecognized net gain on pension plans 1,083 1,083 Accumulated other comprehensive loss, net of tax $ (24,434 ) $ (19,315 ) As of September 30, 2018 and March 31, 2018 , no amounts were reclassified from accumulated other comprehensive income into earnings.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on income available to common stockholders and the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on income available to common stockholders and the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options and restricted stock units ("RSUs"). Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and nonvested RSUs, are included in the diluted earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and restricted stock units has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, (In thousands, except per share data) 2018 2017 2018 2017 Numerator Net income $ 30,841 $ 30,705 $ 65,307 $ 64,464 Denominator Denominator for basic earnings per share — weighted average shares outstanding 51,841 53,098 52,238 53,068 Dilutive effect of nonvested restricted stock units and options issued to employees and directors 312 441 307 456 Denominator for diluted earnings per share 52,153 53,539 52,545 53,524 Earnings per Common Share: Basic earnings per share $ 0.59 $ 0.58 $ 1.25 $ 1.21 Diluted earnings per share $ 0.59 $ 0.57 $ 1.24 $ 1.20 For the three months ended September 30, 2018 and 2017 , there were 0.7 million and 0.4 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the six months ended September 30, 2018 and 2017 , there were 0.5 million and 0.4 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, RSUs and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, an increase of the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and an extension of the term of the Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan. During the three and six months ended September 30, 2018 , pre-tax share-based compensation costs charged against income were $2.7 million and $4.3 million , respectively, and the related income tax benefit recognized was $0.5 million and $0.8 million , respectively. During the three and six months ended September 30, 2017 , pre-tax share-based compensation costs charged against income were $3.0 million and $4.7 million , respectively, and the related income tax benefit recognized was $1.0 million and $1.5 million , respectively. At September 30, 2018 , there were $9.4 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 1.0 year. The total fair value of options and RSUs vested during the six months ended September 30, 2018 and 2017 was $11.9 million and $6.7 million , respectively. For the six months ended September 30, 2018 and 2017 , we received cash from the exercise of stock options of $1.0 million and $1.5 million , respectively. For the six months ended September 30, 2018 and 2017 , we realized $1.2 million and $1.2 million , respectively, in tax benefits from the tax deductions resulting from RSU issuances and stock option exercises. At September 30, 2018 , there were 1.8 million shares available for issuance under the Plan. On May 7, 2018, the Compensation and Talent Management Committee of our Board of Directors granted 103,406 performance stock units, 100,399 RSUs and stock options to acquire 294,484 shares of our common stock to certain executive officers and employees under the Plan. The stock options were granted at an exercise price of $29.46 per share, which was equal to the closing price for our common stock on the date of the grant. Each of the independent members of the Board of Directors received a grant under the Plan of 3,779 RSUs on July 31, 2018. R estricted Stock Units RSUs granted to employees under the Plan generally vest in three years, primarily upon the attainment of certain time vesting thresholds, and, in the case of performance share units, may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The RSUs provide for accelerated vesting if there is a change of control, as defined in the Plan. The RSUs granted to employees generally vest either ratably over three years or in their entirety on the three -year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the RSUs, unless otherwise accelerated by the Compensation and Talent Management Committee or, in the case of RSUs granted in May 2017 and 2018, subject to pro-rata vesting in the event of death, disability or retirement. The RSUs granted to directors vest immediately upon grant, and will be settled by delivery to the director of one share of our common stock for each vested RSU promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six -month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the Plan is presented below: RSUs Shares (in thousands) Weighted- Average Grant-Date Fair Value Six Months Ended September 30, 2017 Vested and nonvested at March 31, 2017 350.1 $ 39.29 Granted 105.8 55.61 Vested and issued (53.3 ) 34.30 Forfeited (6.7 ) 49.30 Vested and nonvested at September 30, 2017 395.9 44.15 Vested at September 30, 2017 90.5 29.88 Six Months Ended September 30, 2018 Vested and nonvested at March 31, 2018 393.5 $ 44.13 Granted 226.4 30.09 Vested and issued (175.8 ) 43.05 Forfeited (31.1 ) 48.32 Vested and nonvested at September 30, 2018 413.0 36.58 Vested at September 30, 2018 113.2 31.05 Options The Plan provides that the exercise price of options granted shall be no less than the fair market value of our common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Except in the case of death, disability or retirement, termination of employment prior to vesting will result in forfeiture of the nonvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan. The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options. The weighted-average grant-date fair values of the options granted during the six months ended September 30, 2018 and 2017 were $10.22 and $21.20 , respectively. Six Months Ended September 30, 2018 2017 Expected volatility 29.6 % 35.2 % Expected dividends $ — $ — Expected term in years 6.0 6.0 Risk-free rate 2.9 % 2.2 % A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Six Months Ended September 30, 2017 Outstanding at March 31, 2017 772.3 $ 37.70 Granted 182.8 56.11 Exercised (51.0 ) 28.76 Forfeited or expired (19.0 ) 47.57 Outstanding at September 30, 2017 885.1 41.80 7.5 $ 9,768 Exercisable at September 30, 2017 498.4 32.34 6.3 $ 9,305 Six Months Ended September 30, 2018 Outstanding at March 31, 2018 873.2 $ 41.79 Granted 294.5 29.46 Exercised (37.2 ) 27.60 Forfeited or expired (125.4 ) 47.16 Outstanding at September 30, 2018 1,005.1 38.03 7.3 $ 6,271 Exercisable at September 30, 2018 555.2 37.08 6.4 $ 3,890 The aggregate intrinsic value of options exercised during the six months ended September 30, 2018 was $0.3 million .

Income Taxes

Income Taxes	6 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Act. The Tax Act represents significant U.S. federal tax reform legislation that includes a permanent reduction to the U.S. federal corporate income tax rate. The permanent reduction to the federal corporate income tax rate resulted in a one-time gain of $267.0 million related to the value of our deferred tax liabilities and a gain of $3.2 million related to the lower blended tax rate on our earnings, in the year ended March 31, 2018, resulting in a net gain of $270.2 million . Additionally, the Tax Act subjects certain of our cumulative foreign earnings and profits to U.S. income taxes through a deemed repatriation, which resulted in a charge of $1.9 million in the year ended March 31, 2018. The changes included in the Tax Act are broad and complex. The final transition impacts of the Tax Act may differ from the above estimates, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates we have utilized to calculate the transition impacts, including impacts from changes to current year earnings estimates and foreign exchange rates of foreign subsidiaries. The U.S. Securities and Exchange Commission ("SEC") has issued rules that allow for a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. We currently anticipate finalizing and recording any resulting adjustment by the end of the measurement period. Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective rates used in the calculation of income taxes were 29.1% and 37.7% for the three months ended September 30, 2018 and 2017 , respectively. The effective rates used in the calculation of income taxes were 27.4% and 36.8% for the six months ended September 30, 2018 and 2017 , respectively. The decreases in the effective tax rates for the three and six months ended September 30, 2018 versus the respective prior year periods were primarily related to the Tax Act. The balance in our uncertain tax liability was $10.8 million at September 30, 2018 and at March 31, 2018 . We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in any of the periods presented.

Employee Retirement Plans

Employee Retirement Plans	6 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Retirement Plans	Employee Retirement Plans The primary components of Net Periodic Benefits consist of the following: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2018 2017 2018 2017 Interest cost $ 610 $ 634 1,220 $ 1,263 Expected return on assets (768 ) (725 ) (1,536 ) (1,451 ) Net periodic benefit income $ (158 ) $ (91 ) $ (316 ) $ (188 ) During the six months ended September 30, 2018 , we contributed $0.2 million to our non-qualified defined benefit plan and $1.0 million to the qualified defined benefit plan. During the remainder of fiscal 2019 , we expect to contribute an additional $0.2 million to our non-qualified plan and make no contributions to the qualified plan.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations.

Concentrations of Risk

Concentrations of Risk	6 Months Ended
	Sep. 30, 2018
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products (prior to the sale of our Household Cleaning segment, as discussed in Note 3). We sell our products to mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels. During the three and six months ended September 30, 2018 , approximately 44.7% and 43.5% , respectively, of our gross revenues were derived from our five top selling brands. During the three and six months ended September 30, 2017 , approximately 40.8% and 42.0% , respectively, of our gross revenues were derived from our five top selling brands. Two customers, Walmart and Walgreens, accounted for more than 10% of our gross revenues for certain periods presented. Walmart accounted for approximately 23.6% and 24.1% , respectively, of our gross revenues for the three and six months ended September 30, 2018 . Walgreens accounted for approximately 10.0% and 9.3% , respectively, of our gross revenues for the three and six months ended September 30, 2018 . Walmart accounted for approximately 25.3% and 25.4% , respectively, of our gross revenues for the three and six months ended September 30, 2017 . Walgreens accounted for approximately 8.7% and 8.9% , respectively, of our gross revenues for the three and six months ended September 30, 2017 . The gross revenues for Walmart and Walgreens are included in our North American OTC Healthcare segment and Household Cleaning segment (prior to the sale of our Household Cleaning segment on July 2, 2018). Our product distribution in the United States is managed by a third party through one primary distribution center near St. Louis, Missouri, and we operate one manufacturing facility located in Lynchburg, Virginia. A serious disruption, caused by performance or contractual issues with the third party distribution manager or by earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. Any disruption as a result of third party performance at our distribution center could result in increased costs, expense, shipping times, customer fees and penalties. In addition, any serious disruption to our Lynchburg manufacturing facility could materially impair our ability to manufacture many of our products, which would also limit our ability to provide products to customers in a timely manner or at a reasonable cost. We could also incur significantly higher costs and experience longer lead times should we be required to reopen or replace our primary distribution center, the third party distribution manager or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At September 30, 2018 , we had relationships with 110 third-party manufacturers. Of those, we had long-term contracts with 34 manufacturers that produced items that accounted for approximately 60.0% of gross sales for the six months ended September 30, 2018 . At September 30, 2017 , we had relationships with 110 third-party manufacturers. Of those, we had long-term contracts with 45 manufacturers that produced items that accounted for approximately 79.5% of gross sales for the six months ended September 30, 2017 . The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	6 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Business Segments	Business Segments Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We sold our Household Cleaning segment on July 2, 2018; see Note 3 for further information. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses. The tables below summarize information about our reportable segments. Three Months Ended September 30, 2018 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 215,950 $ 23,407 $ — $ 239,357 Cost of sales 92,007 9,878 — 101,885 Gross profit 123,943 13,529 — 137,472 Advertising and promotion 33,325 3,717 — 37,042 Contribution margin $ 90,618 $ 9,812 $ — 100,430 Other operating expenses 29,506 Operating income 70,924 Other expense 27,405 Income before income taxes 43,519 Provision for income taxes 12,678 Net income $ 30,841 * Intersegment revenues of $1.6 million were eliminated from the North American OTC Healthcare segment. Six Months Ended September 30, 2018 (In thousands) North American OTC International OTC Household Cleaning Consolidated Total segment revenues* $ 430,725 $ 42,801 $ 19,811 $ 493,337 Cost of sales 181,160 17,494 16,588 215,242 Gross profit 249,565 25,307 3,223 278,095 Advertising and promotion 66,583 7,140 430 74,153 Contribution margin $ 182,982 $ 18,167 $ 2,793 203,942 Other operating expenses 60,531 Operating income 143,411 Other expense 53,432 Income before income taxes 89,979 Provision for income taxes 24,672 Net income $ 65,307 * Intersegment revenues of $4.3 million were eliminated from the North American OTC Healthcare segment. Three Months Ended September 30, 2017 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 215,302 $ 20,957 $ 21,767 $ 258,026 Cost of sales 87,184 9,296 17,448 113,928 Gross profit 128,118 11,661 4,319 144,098 Advertising and promotion 35,064 3,593 531 39,188 Contribution margin $ 93,054 $ 8,068 $ 3,788 104,910 Other operating expenses 29,185 Operating income 75,725 Other expense 26,404 Income before income taxes 49,321 Provision for income taxes 18,616 Net income $ 30,705 * Intersegment revenues of $2.3 million were eliminated from the North American OTC Healthcare segment. Six Months Ended September 30, 2017 (In thousands) North American OTC International OTC Household Cleaning Consolidated Total segment revenues* $ 431,117 $ 41,855 $ 41,627 $ 514,599 Cost of sales 173,685 19,246 34,094 227,025 Gross profit 257,432 22,609 7,533 287,574 Advertising and promotion 67,872 7,283 977 76,132 Contribution margin $ 189,560 $ 15,326 $ 6,556 211,442 Other operating expenses 56,762 Operating income 154,680 Other expense 52,671 Income before income taxes 102,009 Provision for income taxes 37,545 Net income $ 64,464 * Intersegment revenues of $3.7 million were eliminated from the North American OTC Healthcare segment. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended September 30, 2018 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 28,638 $ 125 $ — $ 28,763 Cough & Cold 20,492 5,734 — 26,226 Women's Health 61,614 3,270 — 64,884 Gastrointestinal 30,529 7,950 — 38,479 Eye & Ear Care 24,845 2,995 — 27,840 Dermatologicals 25,338 605 — 25,943 Oral Care 23,142 2,727 — 25,869 Other OTC 1,352 1 — 1,353 Household Cleaning — — — — Total segment revenues $ 215,950 $ 23,407 $ — $ 239,357 Six Months Ended September 30, 2018 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 56,896 $ 282 $ — $ 57,178 Cough & Cold 36,706 10,905 — 47,611 Women's Health 125,091 5,527 — 130,618 Gastrointestinal 63,328 13,940 — 77,268 Eye & Ear Care 50,317 5,614 — 55,931 Dermatologicals 50,460 1,137 — 51,597 Oral Care 45,339 5,394 — 50,733 Other OTC 2,588 2 — 2,590 Household Cleaning — — 19,811 19,811 Total segment revenues $ 430,725 $ 42,801 $ 19,811 $ 493,337 Three Months Ended September 30, 2017 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,348 $ 40 $ — $ 29,388 Cough & Cold 21,567 4,659 — 26,226 Women's Health 61,436 1,906 — 63,342 Gastrointestinal 28,323 8,139 — 36,462 Eye & Ear Care 22,535 2,590 — 25,125 Dermatologicals 25,821 524 — 26,345 Oral Care 24,990 3,097 — 28,087 Other OTC 1,282 2 — 1,284 Household Cleaning — — 21,767 21,767 Total segment revenues $ 215,302 $ 20,957 $ 21,767 $ 258,026 Six Months Ended September 30, 2017 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 58,638 $ 549 $ — $ 59,187 Cough & Cold 38,977 9,272 — 48,249 Women's Health 124,581 5,500 — 130,081 Gastrointestinal 58,753 13,872 — 72,625 Eye & Ear Care 47,806 5,645 — 53,451 Dermatologicals 49,952 1,025 — 50,977 Oral Care 49,882 5,989 — 55,871 Other OTC 2,528 3 — 2,531 Household Cleaning — — 41,627 41,627 Total segment revenues $ 431,117 $ 41,855 $ 41,627 $ 514,599 Our total segment revenues by geographic area are as follows: Three Months Ended September 30, Six Months Ended September 30, 2018 2017 2018 2017 United States $ 203,763 $ 225,351 $ 427,240 $ 450,345 Rest of world 35,594 32,675 66,097 64,254 Total $ 239,357 $ 258,026 $ 493,337 $ 514,599 Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: September 30, 2018 North American OTC International OTC Household Consolidated (In thousands) Goodwill $ 580,934 $ 31,510 $ — $ 612,444 Intangible assets Indefinite-lived 2,375,737 78,887 — 2,454,624 Finite-lived, net 254,876 5,570 — 260,446 Intangible assets, net 2,630,613 84,457 — 2,715,070 Total $ 3,211,547 $ 115,967 $ — $ 3,327,514 March 31, 2018 North American OTC International OTC Household Consolidated (In thousands) Goodwill $ 580,934 $ 32,919 $ 6,245 $ 620,098 Intangible assets Indefinite-lived 2,375,736 84,006 30,561 2,490,303 Finite-lived, net 265,356 6,068 19,189 290,613 Intangible assets, net 2,641,092 90,074 49,750 2,780,916 Total $ 3,222,026 $ 122,993 $ 55,995 $ 3,401,014

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	6 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., “ 2019 ”) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three and six months ended September 30, 2018 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2019 . These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2018 .
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates.
Reclassification	Reclassification In accordance with Accounting Standards Update ("ASU") 2017-07, we have reclassified net periodic benefit costs related to our pension plans from general and administrative expense to other (income) expense. The impact of this reclassification on our financial statements was less than $1.0 million .
Recently Adopted and Issued Accounting Standards	Recently Adopted Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606 , including new FASB Accounting Standards Codification ("ASC") 606, which supersedes the revenue recognition requirements in FASB ASC 605. Along with amendments issued in 2015 and 2016, the new guidance eliminates industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue. The core principle of the new guidance is that an entity should recognize revenue for the transfer of goods and services equal to an amount it expects to be entitled to receive for those goods and services. The new standard also requires additional disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The new guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively by recognizing the cumulative effect of initially applying the guidance to all contracts existing at the date of initial application (the modified retrospective method). The ASU, as amended, is effective for annual reporting periods beginning after December 15, 2017. We adopted this guidance effective April 1, 2018 using the modified retrospective transition method and applied it to contracts that were not completed at the adoption date. See Note 2 for our revenue recognition policy. The effects of this recently adopted accounting pronouncement to our consolidated balance sheet as of April 1, 2018 are as follows: (In thousands) Balance March 31, 2018 New Revenue Standard Adjustment Balance April 1, 2018 Accounts receivable, net $ 140,881 $ 5,438 $ 146,319 Inventories 118,547 (1,768 ) 116,779 Other accrued liabilities 52,101 1,925 54,026 Deferred income tax liabilities 442,518 401 442,919 Retained earnings 736,277 1,344 737,621 In March 2017, the FASB issued ASU 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost , which changes the presentation of net periodic benefit cost related to employer sponsored defined benefit plans and other postretirement benefits. Under this ASU, service cost should be included in the same income statement line item as other compensation costs arising from services rendered during the period, while other components of net periodic benefit pension cost should be presented separately outside of operating income. Additionally, only service costs may be capitalized in assets. Entities should apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. The guidance limiting the capitalization of net periodic benefit cost in assets to the service cost component should be applied prospectively. The standard is effective for annual reporting periods beginning after December 15, 2017. The adoption of this standard in the first quarter of 2019 required us to reclassify certain pension costs out of operating income and did not have a material impact on our consolidated financial statements. In March 2018, the FASB issued ASU 2018-05, Income Taxes (Topic 740) . The amendments in this update reflect the income tax accounting implications of the Tax Cuts and Jobs Act ("Tax Act"). See Note 14 for a discussion of the Tax Act, which was signed into law on December 22, 2017, and the impact it has had, and may have, on our business and financial results. In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income . The amendments in this update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. See Note 14 for a discussion of the Tax Act, which was signed into law on December 22, 2017, and the impact it has had, and may have, on our business and financial results. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. We have early adopted ASU 2018-02, and the adoption did not have a material impact on our consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. We adopted this standard effective April 1, 2018, and the adoption did not have a material impact on our consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments . The amendments in this update provide clarification and guidance on eight cash flow classification issues. For public companies, the amendments in this update are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We adopted this standard effective April 1, 2018, and the adoption did not have a material impact on our consolidated financial statements. Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans. The amendments in this update modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans and are effective for public companies for fiscal years ending after December 15, 2020. We do not expect the adoption of this standard to have a material impact on our financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements in Topic 820 and are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We do not expect the adoption of this standard to have a material impact on our financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) . The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our consolidated financial statements and whether to early adopt this ASU. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments . The amendments in this update provide financial statement users with more useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. The amendments to this update are effective for us for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of adopting this guidance on our consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases. The amendments in this update include a new FASB ASC Topic 842, which supersedes Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For public companies, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. In July 2018, further guidance on this topic was issued with ASU 2018-10, Codification Improvements to Topic 842, Leases, which affects narrow aspects of the guidance in ASU 2016-02, and with ASU 2018-11, Leases (Topic 842): Targeted Improvements, which provides an additional transition method to adopt the new lease standard as well as a practical expedient. The required effective dates for the amendments issued in July 2018 are the same as those for Topic 842. We plan to adopt the standard on April 1, 2019. We are in the process of aggregating and evaluating our lease arrangements. Adoption of this standard will result in a material increase in lease-related assets and liabilities recognized on our Consolidated Balance Sheet, but we are unable to quantify the impact at this time.
Revenue Recognition	Revenue Recognition Nature of Goods and Services We recognize revenue from product sales. We primarily ship finished goods to our customers and operate in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning (this segment was sold on July 2, 2018). The segments are based on differences in the nature of products and geographical area. The North America and International OTC Healthcare segments market a variety of personal care and over-the-counter products in the following product groups: Analgesics, Cough & Cold, Women's Health, Gastrointestinal, Eye & Ear Care, Dermatologicals, and Oral Care. Prior to its sale, the Household Cleaning segment focused on the sale of cleaning products. Our products are distinct and separately identifiable on customer contracts or invoices, with each product sale representing a separate performance obligation. We sell consumer products under a variety of brands through a broad distribution platform that includes mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels, all of which sell our products to consumers. See Note 18 for disaggregated revenue information. Satisfaction of Performance Obligations Revenue is recognized when control of a promised good is transferred to a customer, in an amount that reflects the consideration that we expect to be entitled to receive in exchange for that good. This occurs either when finished goods are transferred to a common carrier for delivery to the customer or when product is picked up by the customer or the customer’s carrier. This represents a change in the timing of revenue recognition for some sales. Refer to the table above in Note 1 for disclosure of the adoption date impacts. Once a product has transferred to the common carrier or been picked up by the customer, the customer is able to direct the use of, and obtain substantially all of the remaining benefits from, the product. It is at this point that we have a right to payment and the customer has legal title. Variable Consideration Provisions for certain rebates, customer promotional programs, product returns, and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales. We record an estimate of future product returns concurrent with recording sales, which is made using the most likely amount method which incorporates (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising. We participate in the promotional programs of our customers to enhance the sale of our products. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. The costs of such activities are recorded as a reduction to revenue when the related sale takes place. Estimates of the costs of these promotional programs are derived using the most likely amount method, which incorporates (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. At the completion of the promotional program, the estimated amounts are adjusted to actual results. Practical Expedients Due to the nature (short duration) of our contracts with customers, we apply the practical expedient related to remaining performance obligations disclosure. Remaining performance obligations relate to contracts with a duration of less than one year , in which we have the right to invoice the customer at the time the performance obligation is satisfied for the amount of revenue recognized at that time. Accordingly, we have elected the practical expedient available under ASC 606 not to disclose remaining performance obligations for our contracts. The period between when control of the promised products transfers to the customer and when the customer pays for the products is one year or less. As such, we do not adjust product consideration for the effects of a significant financing component. The amortization period of any asset resulting from incremental costs of obtaining a contract would be one year or less. We expense incremental direct costs of obtaining a contract (broker commissions) when the related sale takes place. We account for shipping and handling costs as fulfillment activities and therefore recognize them upon shipment of goods.

Business and Basis of Present_3

Business and Basis of Presentation (Tables)	6 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Effects of Recently Adopted Accounting Pronouncement	The effects of this recently adopted accounting pronouncement to our consolidated balance sheet as of April 1, 2018 are as follows: (In thousands) Balance March 31, 2018 New Revenue Standard Adjustment Balance April 1, 2018 Accounts receivable, net $ 140,881 $ 5,438 $ 146,319 Inventories 118,547 (1,768 ) 116,779 Other accrued liabilities 52,101 1,925 54,026 Deferred income tax liabilities 442,518 401 442,919 Retained earnings 736,277 1,344 737,621 The impact of adopting ASC 606 on our Condensed Consolidated Statements of Income and Comprehensive Income is as follows: Three Months Ended September 30, 2018 Six Months Ended September 30, 2018 (In thousands) As Reported Impact of Change Without Adoption of ASC 606 As Reported Impact of Change Without Adoption of ASC 606 Total revenues $ 239,357 $ (16,165 ) $ 223,192 $ 493,337 $ (22,110 ) $ 471,227 Cost of sales $ 101,885 $ (6,204 ) $ 95,681 $ 215,242 $ (8,396 ) $ 206,846 Total operating expenses $ 66,548 $ (440 ) $ 66,108 $ 134,684 $ (579 ) $ 134,105 Income before income taxes $ 43,519 $ (9,521 ) $ 33,998 $ 89,979 $ (13,135 ) $ 76,844 Provision for income taxes $ 12,678 $ (2,771 ) $ 9,907 $ 24,672 $ (3,752 ) $ 20,920 Net income $ 30,841 $ (6,750 ) $ 24,091 $ 65,307 $ (9,383 ) $ 55,924

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Reconciliation of Revenue	The effects of this recently adopted accounting pronouncement to our consolidated balance sheet as of April 1, 2018 are as follows: (In thousands) Balance March 31, 2018 New Revenue Standard Adjustment Balance April 1, 2018 Accounts receivable, net $ 140,881 $ 5,438 $ 146,319 Inventories 118,547 (1,768 ) 116,779 Other accrued liabilities 52,101 1,925 54,026 Deferred income tax liabilities 442,518 401 442,919 Retained earnings 736,277 1,344 737,621 The impact of adopting ASC 606 on our Condensed Consolidated Statements of Income and Comprehensive Income is as follows: Three Months Ended September 30, 2018 Six Months Ended September 30, 2018 (In thousands) As Reported Impact of Change Without Adoption of ASC 606 As Reported Impact of Change Without Adoption of ASC 606 Total revenues $ 239,357 $ (16,165 ) $ 223,192 $ 493,337 $ (22,110 ) $ 471,227 Cost of sales $ 101,885 $ (6,204 ) $ 95,681 $ 215,242 $ (8,396 ) $ 206,846 Total operating expenses $ 66,548 $ (440 ) $ 66,108 $ 134,684 $ (579 ) $ 134,105 Income before income taxes $ 43,519 $ (9,521 ) $ 33,998 $ 89,979 $ (13,135 ) $ 76,844 Provision for income taxes $ 12,678 $ (2,771 ) $ 9,907 $ 24,672 $ (3,752 ) $ 20,920 Net income $ 30,841 $ (6,750 ) $ 24,091 $ 65,307 $ (9,383 ) $ 55,924

Divestiture (Tables)

Divestiture (Tables)	6 Months Ended
	Sep. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
Divestiture	The following table sets forth the components of the assets sold and the pre-tax gain recognized on the sale in July 2018: (In thousands) July 2, 2018 Components of assets sold: Inventory $ 6,644 Property, plant and equipment, net 653 Goodwill 6,245 Intangible assets, net 49,315 Assets sold 62,857 Total purchase price received 65,912 (3,055 ) Costs to sell 1,771 Pre-tax gain on divestiture $ (1,284 )

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) September 30, 2018 March 31, 2018 Components of Inventories Packaging and raw materials $ 13,704 $ 13,112 Work in process 237 157 Finished goods 99,628 105,278 Inventories $ 113,569 $ 118,547

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Household Consolidated Balance - March 31, 2018 Goodwill $ 711,104 $ 32,919 $ 71,405 $ 815,428 Accumulated impairment loss (130,170 ) — (65,160 ) (195,330 ) Balance - March 31, 2018 580,934 32,919 6,245 620,098 2019 Reductions — — (6,245 ) (6,245 ) Effects of foreign currency exchange rates — (1,409 ) — (1,409 ) Balance - September 30, 2018 Goodwill 711,104 31,510 65,160 807,774 Accumulated impairment loss (130,170 ) — (65,160 ) (195,330 ) Balance - September 30, 2018 $ 580,934 $ 31,510 $ — $ 612,444

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	6 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Finite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Lived Trademarks Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2018 $ 2,490,303 $ 441,314 $ 2,931,617 Reductions (30,562 ) (34,889 ) (65,451 ) Effects of foreign currency exchange rates (5,117 ) (287 ) (5,404 ) Balance — September 30, 2018 2,454,624 406,138 2,860,762 Accumulated Amortization Balance — March 31, 2018 — 150,701 150,701 Additions — 11,181 11,181 Reductions — (16,136 ) (16,136 ) Effects of foreign currency exchange rates — (54 ) (54 ) Balance — September 30, 2018 — 145,692 145,692 Intangible assets, net — September 30, 2018 $ 2,454,624 $ 260,446 $ 2,715,070
Reconciliation of the Activity Affecting Indefinite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Lived Trademarks Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2018 $ 2,490,303 $ 441,314 $ 2,931,617 Reductions (30,562 ) (34,889 ) (65,451 ) Effects of foreign currency exchange rates (5,117 ) (287 ) (5,404 ) Balance — September 30, 2018 2,454,624 406,138 2,860,762 Accumulated Amortization Balance — March 31, 2018 — 150,701 150,701 Additions — 11,181 11,181 Reductions — (16,136 ) (16,136 ) Effects of foreign currency exchange rates — (54 ) (54 ) Balance — September 30, 2018 — 145,692 145,692 Intangible assets, net — September 30, 2018 $ 2,454,624 $ 260,446 $ 2,715,070

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) September 30, 2018 March 31, 2018 Accrued marketing costs $ 28,457 $ 21,473 Accrued compensation costs 6,523 10,591 Accrued broker commissions 2,113 1,487 Income taxes payable 12,735 1,901 Accrued professional fees 3,877 2,244 Accrued production costs 6,388 7,392 Other accrued liabilities 9,964 7,013 $ 70,057 $ 52,101

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) September 30, 2018 March 31, 2018 2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. $ 600,000 $ 600,000 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. 400,000 400,000 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00%, with a floor of 1.00%, due on January 26, 2024. 838,000 938,000 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 26, 2022. 75,000 75,000 Long-term debt 1,913,000 2,013,000 Less: unamortized debt costs (17,165 ) (20,048 ) Long-term debt, net $ 1,895,835 $ 1,992,952
Aggregate Future Principal Payments	As of September 30, 2018 , aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans, 2012 ABL Revolver and the indentures governing the 6.375% senior unsecured notes due 2024 (the "2016 Senior Notes") and the 5.375% senior unsecured notes due 2021 (the "2013 Senior Notes") are as follows: (In thousands) Year Ending March 31, Amount 2019 (remaining six months ending March 31, 2019) $ — 2020 — 2021 — 2022 475,000 2023 — Thereafter 1,438,000 $ 1,913,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Summary of Carry Amounts and Fair Value Measurements	As such, the 2016 Senior Notes, the 2013 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. See summary below detailing the carrying amounts and estimated fair values of these borrowings at September 30, 2018 and March 31, 2018 . September 30, 2018 March 31, 2018 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2016 Senior Notes $ 600,000 $ 606,000 $ 600,000 $ 610,500 2013 Senior Notes 400,000 400,000 400,000 402,000 2012 Term B-5 Loans 838,000 838,000 938,000 939,173 2012 ABL Revolver 75,000 75,000 75,000 75,000

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consisted of the following at September 30, 2018 and March 31, 2018 : (In thousands) September 30, 2018 March 31, 2018 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (25,517 ) $ (20,398 ) Unrecognized net gain on pension plans 1,083 1,083 Accumulated other comprehensive loss, net of tax $ (24,434 ) $ (19,315 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, (In thousands, except per share data) 2018 2017 2018 2017 Numerator Net income $ 30,841 $ 30,705 $ 65,307 $ 64,464 Denominator Denominator for basic earnings per share — weighted average shares outstanding 51,841 53,098 52,238 53,068 Dilutive effect of nonvested restricted stock units and options issued to employees and directors 312 441 307 456 Denominator for diluted earnings per share 52,153 53,539 52,545 53,524 Earnings per Common Share: Basic earnings per share $ 0.59 $ 0.58 $ 1.25 $ 1.21 Diluted earnings per share $ 0.59 $ 0.57 $ 1.24 $ 1.20

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Restricted Shares	A summary of the RSUs granted under the Plan is presented below: RSUs Shares (in thousands) Weighted- Average Grant-Date Fair Value Six Months Ended September 30, 2017 Vested and nonvested at March 31, 2017 350.1 $ 39.29 Granted 105.8 55.61 Vested and issued (53.3 ) 34.30 Forfeited (6.7 ) 49.30 Vested and nonvested at September 30, 2017 395.9 44.15 Vested at September 30, 2017 90.5 29.88 Six Months Ended September 30, 2018 Vested and nonvested at March 31, 2018 393.5 $ 44.13 Granted 226.4 30.09 Vested and issued (175.8 ) 43.05 Forfeited (31.1 ) 48.32 Vested and nonvested at September 30, 2018 413.0 36.58 Vested at September 30, 2018 113.2 31.05
Fair Value of Options Granted	The weighted-average grant-date fair values of the options granted during the six months ended September 30, 2018 and 2017 were $10.22 and $21.20 , respectively. Six Months Ended September 30, 2018 2017 Expected volatility 29.6 % 35.2 % Expected dividends $ — $ — Expected term in years 6.0 6.0 Risk-free rate 2.9 % 2.2 %
Stock Option Activity	A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Six Months Ended September 30, 2017 Outstanding at March 31, 2017 772.3 $ 37.70 Granted 182.8 56.11 Exercised (51.0 ) 28.76 Forfeited or expired (19.0 ) 47.57 Outstanding at September 30, 2017 885.1 41.80 7.5 $ 9,768 Exercisable at September 30, 2017 498.4 32.34 6.3 $ 9,305 Six Months Ended September 30, 2018 Outstanding at March 31, 2018 873.2 $ 41.79 Granted 294.5 29.46 Exercised (37.2 ) 27.60 Forfeited or expired (125.4 ) 47.16 Outstanding at September 30, 2018 1,005.1 38.03 7.3 $ 6,271 Exercisable at September 30, 2018 555.2 37.08 6.4 $ 3,890

Employee Retirement Plans (Tabl

Employee Retirement Plans (Tables)	6 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Primary Components of Net Periodic Benefits	The primary components of Net Periodic Benefits consist of the following: Three Months Ended September 30, Six Months Ended September 30, (In thousands) 2018 2017 2018 2017 Interest cost $ 610 $ 634 1,220 $ 1,263 Expected return on assets (768 ) (725 ) (1,536 ) (1,451 ) Net periodic benefit income $ (158 ) $ (91 ) $ (316 ) $ (188 )

Business Segments (Tables)

Business Segments (Tables)	6 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Information about our Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended September 30, 2018 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 215,950 $ 23,407 $ — $ 239,357 Cost of sales 92,007 9,878 — 101,885 Gross profit 123,943 13,529 — 137,472 Advertising and promotion 33,325 3,717 — 37,042 Contribution margin $ 90,618 $ 9,812 $ — 100,430 Other operating expenses 29,506 Operating income 70,924 Other expense 27,405 Income before income taxes 43,519 Provision for income taxes 12,678 Net income $ 30,841 * Intersegment revenues of $1.6 million were eliminated from the North American OTC Healthcare segment. Six Months Ended September 30, 2018 (In thousands) North American OTC International OTC Household Cleaning Consolidated Total segment revenues* $ 430,725 $ 42,801 $ 19,811 $ 493,337 Cost of sales 181,160 17,494 16,588 215,242 Gross profit 249,565 25,307 3,223 278,095 Advertising and promotion 66,583 7,140 430 74,153 Contribution margin $ 182,982 $ 18,167 $ 2,793 203,942 Other operating expenses 60,531 Operating income 143,411 Other expense 53,432 Income before income taxes 89,979 Provision for income taxes 24,672 Net income $ 65,307 * Intersegment revenues of $4.3 million were eliminated from the North American OTC Healthcare segment. Three Months Ended September 30, 2017 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 215,302 $ 20,957 $ 21,767 $ 258,026 Cost of sales 87,184 9,296 17,448 113,928 Gross profit 128,118 11,661 4,319 144,098 Advertising and promotion 35,064 3,593 531 39,188 Contribution margin $ 93,054 $ 8,068 $ 3,788 104,910 Other operating expenses 29,185 Operating income 75,725 Other expense 26,404 Income before income taxes 49,321 Provision for income taxes 18,616 Net income $ 30,705 * Intersegment revenues of $2.3 million were eliminated from the North American OTC Healthcare segment. Six Months Ended September 30, 2017 (In thousands) North American OTC International OTC Household Cleaning Consolidated Total segment revenues* $ 431,117 $ 41,855 $ 41,627 $ 514,599 Cost of sales 173,685 19,246 34,094 227,025 Gross profit 257,432 22,609 7,533 287,574 Advertising and promotion 67,872 7,283 977 76,132 Contribution margin $ 189,560 $ 15,326 $ 6,556 211,442 Other operating expenses 56,762 Operating income 154,680 Other expense 52,671 Income before income taxes 102,009 Provision for income taxes 37,545 Net income $ 64,464 * Intersegment revenues of $3.7 million were eliminated from the North American OTC Healthcare segment.
Information about our Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended September 30, 2018 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 28,638 $ 125 $ — $ 28,763 Cough & Cold 20,492 5,734 — 26,226 Women's Health 61,614 3,270 — 64,884 Gastrointestinal 30,529 7,950 — 38,479 Eye & Ear Care 24,845 2,995 — 27,840 Dermatologicals 25,338 605 — 25,943 Oral Care 23,142 2,727 — 25,869 Other OTC 1,352 1 — 1,353 Household Cleaning — — — — Total segment revenues $ 215,950 $ 23,407 $ — $ 239,357 Six Months Ended September 30, 2018 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 56,896 $ 282 $ — $ 57,178 Cough & Cold 36,706 10,905 — 47,611 Women's Health 125,091 5,527 — 130,618 Gastrointestinal 63,328 13,940 — 77,268 Eye & Ear Care 50,317 5,614 — 55,931 Dermatologicals 50,460 1,137 — 51,597 Oral Care 45,339 5,394 — 50,733 Other OTC 2,588 2 — 2,590 Household Cleaning — — 19,811 19,811 Total segment revenues $ 430,725 $ 42,801 $ 19,811 $ 493,337 Three Months Ended September 30, 2017 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,348 $ 40 $ — $ 29,388 Cough & Cold 21,567 4,659 — 26,226 Women's Health 61,436 1,906 — 63,342 Gastrointestinal 28,323 8,139 — 36,462 Eye & Ear Care 22,535 2,590 — 25,125 Dermatologicals 25,821 524 — 26,345 Oral Care 24,990 3,097 — 28,087 Other OTC 1,282 2 — 1,284 Household Cleaning — — 21,767 21,767 Total segment revenues $ 215,302 $ 20,957 $ 21,767 $ 258,026 Six Months Ended September 30, 2017 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 58,638 $ 549 $ — $ 59,187 Cough & Cold 38,977 9,272 — 48,249 Women's Health 124,581 5,500 — 130,081 Gastrointestinal 58,753 13,872 — 72,625 Eye & Ear Care 47,806 5,645 — 53,451 Dermatologicals 49,952 1,025 — 50,977 Oral Care 49,882 5,989 — 55,871 Other OTC 2,528 3 — 2,531 Household Cleaning — — 41,627 41,627 Total segment revenues $ 431,117 $ 41,855 $ 41,627 $ 514,599
Information about our Segment Revenues by Geographic Area	Our total segment revenues by geographic area are as follows: Three Months Ended September 30, Six Months Ended September 30, 2018 2017 2018 2017 United States $ 203,763 $ 225,351 $ 427,240 $ 450,345 Rest of world 35,594 32,675 66,097 64,254 Total $ 239,357 $ 258,026 $ 493,337 $ 514,599
Information about our Consolidated Goodwil and Intangible Assets Allocated to Reportable Segments	Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: September 30, 2018 North American OTC International OTC Household Consolidated (In thousands) Goodwill $ 580,934 $ 31,510 $ — $ 612,444 Intangible assets Indefinite-lived 2,375,737 78,887 — 2,454,624 Finite-lived, net 254,876 5,570 — 260,446 Intangible assets, net 2,630,613 84,457 — 2,715,070 Total $ 3,211,547 $ 115,967 $ — $ 3,327,514 March 31, 2018 North American OTC International OTC Household Consolidated (In thousands) Goodwill $ 580,934 $ 32,919 $ 6,245 $ 620,098 Intangible assets Indefinite-lived 2,375,736 84,006 30,561 2,490,303 Finite-lived, net 265,356 6,068 19,189 290,613 Intangible assets, net 2,641,092 90,074 49,750 2,780,916 Total $ 3,222,026 $ 122,993 $ 55,995 $ 3,401,014

Business and Basis of Present_4

Business and Basis of Presentation (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
General and administrative (less than $1.0 million)	$ (24,034)	$ (21,999)	$ (47,975)	$ (42,409)
Other expense (income), net	$ 335	$ (432)	422	$ (506)
Accounting Standards Update 2017-07
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
General and administrative (less than $1.0 million)			1,000
Other expense (income), net			$ 1,000

Business and Basis of Present_5

Business and Basis of Presentation (Effects of Recently Adopted Accounting Pronouncement) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Apr. 01, 2018	Mar. 31, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	$ 153,849	$ 146,319	$ 140,881
Inventories	113,569	116,779	118,547
Other accrued liabilities	70,057	54,026	52,101
Deferred income tax liabilities	440,853	442,919	442,518
Retained earnings	$ 802,927	737,621	736,277
Calculated under Revenue Guidance in Effect before Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net			140,881
Inventories			118,547
Other accrued liabilities			52,101
Deferred income tax liabilities			442,518
Retained earnings			$ 736,277
Difference between Revenue Guidance in Effect before and after Topic 606 | New Revenue Standard Adjustment
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net		5,438
Inventories		(1,768)
Other accrued liabilities		1,925
Deferred income tax liabilities		401
Retained earnings		$ 1,344

Revenue Recognition (Narrative)

Revenue Recognition (Narrative) (Details)	6 Months Ended
	Sep. 30, 2018segment
Revenue from Contract with Customer [Abstract]
Number of operating segments	3
Contract duration	less than one year
Amortization period	1 year

Revenue Recognition (Revenue Re

Revenue Recognition (Revenue Reconciliation) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total revenues	$ 239,357	$ 258,026	$ 493,337	$ 514,599
Cost of sales	101,885	113,928	215,242	227,025
Total operating expenses	66,548	68,373	134,684	132,894
Income before income taxes	43,519	49,321	89,979	102,009
Provision for income taxes	12,678	18,616	24,672	37,545
Net income	30,841	$ 30,705	65,307	$ 64,464
Impact of Change | New Revenue Standard Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total revenues	(16,165)		(22,110)
Cost of sales	(6,204)		(8,396)
Total operating expenses	(440)		(579)
Income before income taxes	(9,521)		(13,135)
Provision for income taxes	(2,771)		(3,752)
Net income	(6,750)		(9,383)
Without Adoption of ASC 606
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total revenues	223,192		471,227
Cost of sales	95,681		206,846
Total operating expenses	66,108		134,105
Income before income taxes	33,998		76,844
Provision for income taxes	9,907		20,920
Net income	$ 24,091		$ 55,924

Divestiture (Details)

Divestiture (Details) - Household Cleaning - Disposed of by sale $ in Thousands	Jul. 02, 2018USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventory	$ 6,644
Property, plant and equipment, net	653
Goodwill	6,245
Intangible assets, net	49,315
Assets sold	62,857
Total purchase price received	65,912
Pre-tax gross gain on divestitures	(3,055)
Costs to sell	1,771
Pre-tax gain on divestiture	$ (1,284)

Inventories (Components of Inv

Inventories (Components of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Apr. 01, 2018	Mar. 31, 2018
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 13,704		$ 13,112
Work in process	237		157
Finished goods	99,628		105,278
Inventories	113,569	$ 116,779	118,547
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 3,300		$ 4,200

Goodwill (Schedule of Segment G

Goodwill (Schedule of Segment Goodwill) (Details) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2018	Mar. 31, 2018
Goodwill [Line Items]
Goodwill	$ 807,774	$ 815,428
Accumulated impairment loss	(195,330)	(195,330)
Goodwill [Roll Forward]
Balance — March 31, 2018	620,098
2019 Reductions	(6,245)
Effects of foreign currency exchange rates	(1,409)
Balance - September 30, 2018	612,444
North American OTC Healthcare
Goodwill [Line Items]
Goodwill	711,104	711,104
Accumulated impairment loss	(130,170)	(130,170)
Goodwill [Roll Forward]
Balance — March 31, 2018	580,934
2019 Reductions	0
Effects of foreign currency exchange rates	0
Balance - September 30, 2018	580,934
International OTC Healthcare
Goodwill [Line Items]
Goodwill	31,510	32,919
Accumulated impairment loss	0	0
Goodwill [Roll Forward]
Balance — March 31, 2018	32,919
2019 Reductions	0
Effects of foreign currency exchange rates	(1,409)
Balance - September 30, 2018	31,510
Household Cleaning
Goodwill [Line Items]
Goodwill	65,160	71,405
Accumulated impairment loss	(65,160)	$ (65,160)
Goodwill [Roll Forward]
Balance — March 31, 2018	6,245
2019 Reductions	(6,245)
Effects of foreign currency exchange rates	0
Balance - September 30, 2018	$ 0

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2018	Mar. 31, 2018
Goodwill [Line Items]
Decrease in goodwill related to sell of segment	$ 6,245,000
Goodwill impairment		$ 0
Household Cleaning
Goodwill [Line Items]
Decrease in goodwill related to sell of segment	$ 6,245,000

Intangible Assets, net (Schedul

Intangible Assets, net (Schedule of Reconciliation of Activity Affecting Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2018
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-Lived Trademarks, beginning balance			$ 2,490,303
Indefinite-Lived Trademarks, ending balance	$ 2,454,624		2,454,624
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-Lived Trademarks and Customer Relationships, accumulated amortization, beginning balance			150,701
Accumulated amortization, additions	5,400	$ 5,800	11,181	$ 11,700
Accumulated amortization, reductions			(16,136)
Accumulated amortization, effects of foreign exchange rates			(54)
Finite-Lived Trademarks and Customer Relationships, accumulated amortization, ending balance	145,692		145,692
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance			2,931,617
Totals, gross, reductions			(65,451)
Totals, effects of foreign currency exchange rate			(5,404)
Totals, gross, ending balance	2,860,762		2,860,762
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived, net	260,446		260,446		$ 290,613
Intangible Assets, Net [Abstract]
Intangible assets, net	2,715,070		2,715,070		$ 2,780,916
Finite-Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-Lived Trademarks and Customer Relationships, beginning balance			441,314
Finite-Lived Trademarks and Customer Relationships, reductions			(34,889)
Finite-Lived Trademarks and Customer Relationships, effects of foreign currency exchange rate			(287)
Finite-Lived Trademarks and Customer Relationships, ending balance	406,138		406,138
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-Lived Trademarks and Customer Relationships, accumulated amortization, beginning balance			150,701
Accumulated amortization, additions			11,181
Accumulated amortization, reductions			(16,136)
Accumulated amortization, effects of foreign exchange rates			(54)
Finite-Lived Trademarks and Customer Relationships, accumulated amortization, ending balance	145,692		145,692
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived, net	260,446		260,446
Indefinite-Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-Lived Trademarks, beginning balance			2,490,303
Indefinite-Lived Trademarks, reductions			(30,562)
Indefinite Lived Trademarks, effects of foreign currency exchange rate			(5,117)
Indefinite-Lived Trademarks, ending balance	$ 2,454,624		$ 2,454,624

Intangible Assets, net (Narrati

Intangible Assets, net (Narrative) (Details) - USD ($) $ in Thousands	Jul. 02, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Schedule of Intangible Assets [Line Items]
Amortization expense		$ 5,400	$ 5,800	$ 11,181	$ 11,700
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of the year		10,700		10,700
2,020		21,500		21,500
2,021		21,000		21,000
2,022		20,600		20,600
2,023		20,600		20,600
2,024		$ 20,600		$ 20,600
Trademarks | Household Cleaning
Schedule of Intangible Assets [Line Items]
Finite-lived intangibles, written off related to sale	$ (18,800)
Indefinite-Lived Trademarks | Household Cleaning
Schedule of Intangible Assets [Line Items]
Indefinite-lived intangibles, written off related to sale	$ (30,500)

Other Accrued Liabilities (Summ

Other Accrued Liabilities (Summary of Accrued Liabilities and Accounts Payable) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Apr. 01, 2018	Mar. 31, 2018
Payables and Accruals [Abstract]
Accrued marketing costs	$ 28,457		$ 21,473
Accrued compensation costs	6,523		10,591
Accrued broker commissions	2,113		1,487
Income taxes payable	12,735		1,901
Accrued professional fees	3,877		2,244
Accrued production costs	6,388		7,392
Other accrued liabilities	9,964		7,013
Total other accrued liabilities	$ 70,057	$ 54,026	$ 52,101

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details) - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Line of credit facility, amount outstanding	$ 1,895,835,000	$ 1,992,952,000
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, amount outstanding	75,000,000
Line of credit facility, additional borrowing capacity	$ 85,000,000
Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	6.375%
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	5.375%

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 1,913,000	$ 2,013,000
Less: unamortized debt costs	(17,165)	(20,048)
Long-term debt, net	1,895,835	1,992,952
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Total long-term debt (including current portion)	75,000	75,000
Long-term debt, net	$ 75,000
Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	6.375%
Total long-term debt (including current portion)	$ 600,000	600,000
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	5.375%
Total long-term debt (including current portion)	$ 400,000	400,000
Term B-5 Loans | 2012 Senior Notes
Debt Instrument [Line Items]
Total long-term debt (including current portion)	$ 838,000	$ 938,000
Term B-5 Loans | 2012 Senior Notes | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)	2.00%
Debt instrument, variable rate, minimum (as percent)	0.00%
Term B-5 Loans | 2012 Senior Notes | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)	1.00%
Debt instrument, variable rate, minimum (as percent)	1.00%

Long-Term Debt (Maturities of L

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Mar. 31, 2018
Aggregate Future Principal Payments
2019 (remaining six months ending March 31, 2019)	$ 0
2,020	0
2,021	0
2,022	475,000
2,023	0
Thereafter	1,438,000
Total long-term debt (including current portion)	$ 1,913,000	$ 2,013,000

Fair Value Measurements (Summar

Fair Value Measurements (Summary of Carrying Amounts and Estimated Fair Values) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Mar. 31, 2018
Senior Notes | 2016 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 600,000	$ 600,000
Senior Notes | 2013 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	400,000	400,000
Term Loans | Term B-4 Loans | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	838,000	938,000
Revolving Credit Facility | 2012 ABL Revolver | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	75,000	75,000
Fair Value, Measurements, Recurring | Senior Notes | 2016 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	606,000	610,500
Fair Value, Measurements, Recurring | Senior Notes | 2013 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	400,000	402,000
Fair Value, Measurements, Recurring | Term Loans | Term B-4 Loans | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	838,000	939,173
Fair Value, Measurements, Recurring | Revolving Credit Facility | 2012 ABL Revolver | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	$ 75,000	$ 75,000

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2018vote$ / sharesshares	Sep. 30, 2017$ / sharesshares	Sep. 30, 2018USD ($)vote$ / sharesshares	Sep. 30, 2017$ / sharesshares	Mar. 31, 2018$ / sharesshares
Class of Stock [Line Items]
Common stock, shares authorized (in shares) | shares	250,000,000		250,000,000		250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) | shares	5,000,000		5,000,000		5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1		1
Dividends declared on common stock | $			$ 0
Stock repurchased during period (in shares) | shares			1,449,750
Stock acquired, average cost per share (in USD per share) | $ / shares			$ 34.47
Treasury stock acquired | $			$ 50,000,000
Restricted Shares
Class of Stock [Line Items]
Stock repurchased during period (in shares) | shares	0	933	68,939	20,549
Stock acquired, average cost per share (in USD per share) | $ / shares		$ 51.60	$ 33.09	$ 52.33

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Components of AOCI) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2018	Mar. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	$ 1,193,238,000	$ 1,178,610,000
Reclassification from accumulated other comprehensive loss into earnings	0	0
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	(25,517,000)	(20,398,000)
Unrecognized net gain on pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	1,083,000	1,083,000
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of accumulated other comprehensive loss	$ (24,434,000)	$ (19,315,000)

Earnings Per Share (Computation

Earnings Per Share (Computation of Basis and Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Numerator
Net income	$ 30,841	$ 30,705	$ 65,307	$ 64,464
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	51,841	53,098	52,238	53,068
Dilutive effect of nonvested restricted stock units and options issued to employees and directors (in shares)	312	441	307	456
Denominator for diluted earnings per share (in shares)	52,153	53,539	52,545	53,524
Earnings per Common Share:
Basic earnings per share (in USD per share)	$ 0.59	$ 0.58	$ 1.25	$ 1.21
Diluted earnings per share (in USD per share)	$ 0.59	$ 0.57	$ 1.24	$ 1.20

Earnings Per Share (Antidilutiv

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0.7	0.4	0.5	0.4

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 31, 2018	May 07, 2018	May 31, 2014	Jun. 30, 2014	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation, Aggregate Disclosures:
Maximum number of shares per participant, 12 month period (in shares)			1,000,000	2,500,000
Extension of plan term				10 years
Share-based compensation costs charged against income					$ 2,700	$ 3,000	$ 4,300	$ 4,700
Tax benefit recognized from share-based compensation expense					500	$ 1,000	800	1,500
Unrecognized compensation costs related to nonvested awards					$ 9,400		$ 9,400
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition							1 year
Total fair value of vested shares							$ 11,900	6,700
Proceeds from exercise of stock options							1,028	1,466
Tax benefit realized from exercise of stock options							$ 1,200	$ 1,200
Shares available for issuance under the Plan (in shares)					1,800,000		1,800,000
Stock options granted (in shares)							294,500	182,800
Options, Additional Disclosures:
Options granted, weighted-average grant-date fair value (in USD per share)							$ 10.22	$ 21.20
Options exercised, aggregate intrinsic value							$ 300
Performance Shares
Share-based Compensation, Aggregate Disclosures:
Share grants in period (in shares)		103,406
Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Share grants in period (in shares)		100,399					226,400	105,800
Restricted Stock Units (RSUs) | Employee
Restricted Shares
Award vesting period							3 years
Restricted Stock Units (RSUs) | Employee | Maximum
Restricted Shares
Award vesting period							3 years
Restricted Stock Units (RSUs) | Director
Share-based Compensation, Aggregate Disclosures:
Share grants in period (in shares)	3,779
Restricted Shares
Number of common shares into which each RSU may be converted (in shares)							1
Period following director's term in which RSUs may be settled							6 months
Stock Options
Share-based Compensation, Aggregate Disclosures:
Stock options granted (in shares)		294,484
Stock options granted, exercise price (in USD per share)		$ 29.46
Stock Options | Minimum
Restricted Shares
Award vesting period							3 years
Stock Options | Maximum
Restricted Shares
Award vesting period							5 years
Options, Additional Disclosures:
Award exercisability period, from date of grant							10 years
Long-term Equity Incentive Plan, 2005
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan (in shares)			5,000,000
Number of additional shares authorized (in shares)				1,800,000

Share-Based Compensation (Restr

Share-Based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares	May 07, 2018	Sep. 30, 2018	Sep. 30, 2017
Shares
Outstanding, beginning of period (in shares)		393,500	350,100
Granted (in shares)	100,399	226,400	105,800
Vested and issued (in shares)		(175,800)	(53,300)
Forfeited (in shares)		(31,100)	(6,700)
Outstanding, end of period (in shares)		413,000	395,900
Vested, end of period (in shares)		113,200	90,500
Weighted- Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)		$ 44.13	$ 39.29
Granted, weighted-average grant-date fair value (in USD per share)		30.09	55.61
Vested and issued, weighted-average grant-date fair value (in USD per share)		43.05	34.30
Forfeited, weighted-average grant-date fair value (in USD per share)		48.32	49.30
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)		36.58	44.15
Vested, end of period, weighted-average grant-date fair value (in USD per share)		$ 31.05	$ 29.88

Share-Based Compensation (Stock

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	29.60%	35.20%
Expected dividends	$ 0	$ 0
Expected term in years	6 years	6 years
Risk-free rate	2.90%	2.20%

Share-Based Compensation (Sto_2

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Shares
Outstanding, beginning of period (in shares)	873,200	772,300
Granted (in shares)	294,500	182,800
Exercised (in shares)	(37,200)	(51,000)
Forfeited or expired (in shares)	(125,400)	(19,000)
Outstanding, end of period (in shares)	1,005,100	885,100
Exercisable, end of period (in shares)	555,200	498,400
Weighted- Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 41.79	$ 37.70
Granted, weighted-average exercise price (in USD per share)	29.46	56.11
Exercised, weighted-average exercise price (in USD per share)	27.60	28.76
Forfeited or expired, weighted-average exercise price (in USD per share)	47.16	47.57
Outstanding, end of period, weighted-average exercise price (in USD per share)	38.03	41.80
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 37.08	$ 32.34
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	7 years 3 months 18 days	7 years 6 months
Exercisable, end of period, weighted-average remaining contractual term	6 years 4 months 24 days	6 years 3 months 18 days
Outstanding, end of period, aggregate intrinsic value	$ 6,271	$ 9,768
Exercisable, end of period, aggregate intrinsic value	$ 3,890	$ 9,305

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Net gain related to value of deferred tax liabilities					$ 267
Net gain related to lower blended rate					3.2
Net gain					270.2
Tax cuts and jobs act of 2017, incomplete accounting, transition tax for foreign earnings, provisional income tax expense					1.9
Effective income tax rate (percent)	29.10%	37.70%	27.40%	36.80%
Uncertain tax liability	$ 10.8		$ 10.8		$ 10.8

Employee Retirement Plans (Expe

Employee Retirement Plans (Expected Return on Plan Assets) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Interest cost	$ 610	$ 634	$ 1,220	$ 1,263
Expected return on assets	(768)	(725)	(1,536)	(1,451)
Net periodic benefit income	$ (158)	$ (91)	$ (316)	$ (188)

Employee Retirement Plans (Narr

Employee Retirement Plans (Narrative) (Details)	6 Months Ended
	Sep. 30, 2018USD ($)
Non-qualified Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions	$ 200,000
Expected employer contributions, remainder of fiscal year	200,000
Qualified Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions	1,000,000
Expected employer contributions, remainder of fiscal year	$ 0

Concentrations of Risk (Narrati

Concentrations of Risk (Narrative) (Details) - manufacturer	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Concentration Risk [Line Items]
Number of third-party manufacturers	110	110	110	110
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage (percent)	23.60%	25.30%	24.10%	25.40%
Sales | Customer Concentration Risk | Walgreens
Concentration Risk [Line Items]
Concentration risk, percentage (percent)	10.00%	8.70%	9.30%	8.90%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (percent)			60.00%	79.50%
Number of third-party manufacturers with long-term contracts			34	45
Top 5 brands | Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (percent)	44.70%	40.80%	43.50%	42.00%

Business Segments (Information

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting Information, Profit (Loss):
Total revenues	$ 239,357	$ 258,026	$ 493,337	$ 514,599
Cost of sales	101,885	113,928	215,242	227,025
Gross profit	137,472	144,098	278,095	287,574
Advertising and promotion	37,042	39,188	74,153	76,132
Contribution margin	100,430	104,910	203,942	211,442
Other operating expenses	29,506	29,185	60,531	56,762
Operating income	70,924	75,725	143,411	154,680
Other expense	27,405	26,404	53,432	52,671
Income before income taxes	43,519	49,321	89,979	102,009
Provision for income taxes	12,678	18,616	24,672	37,545
Net income	30,841	30,705	65,307	64,464
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	215,950	215,302	430,725	431,117
Cost of sales	92,007	87,184		173,685
Gross profit	123,943	128,118		257,432
Advertising and promotion	33,325	35,064		67,872
Contribution margin	90,618	93,054		189,560
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	23,407	20,957	42,801	41,855
Cost of sales	9,878	9,296		19,246
Gross profit	13,529	11,661		22,609
Advertising and promotion	3,717	3,593		7,283
Contribution margin	9,812	8,068		15,326
Household Cleaning
Segment Reporting Information, Profit (Loss):
Total revenues	0	21,767	19,811	41,627
Cost of sales	0	17,448		34,094
Gross profit	0	4,319		7,533
Advertising and promotion	0	531		977
Contribution margin	0	3,788		6,556
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues			430,725
Cost of sales			181,160
Gross profit			249,565
Advertising and promotion			66,583
Contribution margin			182,982
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues			42,801
Cost of sales			17,494
Gross profit			25,307
Advertising and promotion			7,140
Contribution margin			18,167
Operating Segments | Household Cleaning
Segment Reporting Information, Profit (Loss):
Total revenues			19,811
Cost of sales			16,588
Gross profit			3,223
Advertising and promotion			430
Contribution margin			2,793
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	$ (1,600)	$ (2,300)	$ (4,300)	$ (3,700)

Business Segments (Revenue) (De

Business Segments (Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 239,357	$ 258,026	$ 493,337	$ 514,599
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,763	29,388	57,178	59,187
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	26,226	26,226	47,611	48,249
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	64,884	63,342	130,618	130,081
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	38,479	36,462	77,268	72,625
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	27,840	25,125	55,931	53,451
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	25,943	26,345	51,597	50,977
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	25,869	28,087	50,733	55,871
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,353	1,284	2,590	2,531
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	21,767	19,811	41,627
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	215,950	215,302	430,725	431,117
North American OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,638	29,348	56,896	58,638
North American OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	20,492	21,567	36,706	38,977
North American OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	61,614	61,436	125,091	124,581
North American OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	30,529	28,323	63,328	58,753
North American OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	24,845	22,535	50,317	47,806
North American OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	25,338	25,821	50,460	49,952
North American OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	23,142	24,990	45,339	49,882
North American OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,352	1,282	2,588	2,528
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	23,407	20,957	42,801	41,855
International OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	125	40	282	549
International OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	5,734	4,659	10,905	9,272
International OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,270	1,906	5,527	5,500
International OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	7,950	8,139	13,940	13,872
International OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,995	2,590	5,614	5,645
International OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	605	524	1,137	1,025
International OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,727	3,097	5,394	5,989
International OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1	2	2	3
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	21,767	19,811	41,627
Household Cleaning | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 0	$ 21,767	$ 19,811	$ 41,627

Business Segments (Revenue by G

Business Segments (Revenue by Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 239,357	$ 258,026	$ 493,337	$ 514,599
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	203,763	225,351	427,240	450,345
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 35,594	$ 32,675	$ 66,097	$ 64,254

Business Segments (Goodwill and

Business Segments (Goodwill and Intangible Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Mar. 31, 2018
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 612,444	$ 620,098
Intangible assets
Indefinite-lived	2,454,624	2,490,303
Finite-lived, net	260,446	290,613
Intangible assets, net	2,715,070	2,780,916
Total	3,327,514	3,401,014
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	580,934	580,934
Intangible assets
Indefinite-lived	2,375,737	2,375,736
Finite-lived, net	254,876	265,356
Intangible assets, net	2,630,613	2,641,092
Total	3,211,547	3,222,026
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	31,510	32,919
Intangible assets
Indefinite-lived	78,887	84,006
Finite-lived, net	5,570	6,068
Intangible assets, net	84,457	90,074
Total	115,967	122,993
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	0	6,245
Intangible assets
Indefinite-lived	0	30,561
Finite-lived, net	0	19,189
Intangible assets, net	0	49,750
Total	$ 0	$ 55,995